We are involved in every step of the drug development process, across all business areas
A medicinal product goes through a long cycle of development. From research and development (R&D) to launching a product on the market, it can take up to ten years. Each stage of this cycle involves the teamwork of business areas and specialists whose expertise is vital to creating products that make a difference in patient lives.
Our R&D is focused on five main therapeutic areas: cardiovascular disease, diabetes, cancer, neuropsychiatric diseases, and immune-inflammatory diseases. We have long been a leader in the field of cardiology and we aim to secure a place of prominence in the area of immune-inflammatory diseases.
We have 16 clinical and pharmaceutical manufacturing centres worldwide—2 in France and 4 for generics—which produce 617 million boxes of products each year.
Our cross-disciplinary functions are key in a world that is increasingly regulated and progressively interconnected.
Our R&D is specialized in 5 main therapeutic areas: diabetes, oncology, cardiology, neuropsychiatric diseases, and immune-inflammatory diseases.
We are committed to providing the most accurate and up-to-date medical information possible in each of our subsidiaries worldwide.
The primary purpose of our medical affairs is to add value to Servier medicines and provide therapeutic solutions to medical professionals and patients.
Working in partnership with us means having a solid link with dedicated experts, the ability to establish agreements in more than 90 countries.